The NHS are testing a cannabis product for the first time:
The makers of the MediPen vaporiser are confident that by setting a precedent for testing cannabis products with this reputable body, it will have a huge impact on the public’s perception of cannabis.
A cannabidiol (CBD) vaporiser that has helped thousands of people suffering from a variety of conditions is being tested by an NHS unit, an unprecedented step that could increase scrutiny on cannabis’ medical benefits and have a huge impact on the UK’s legislation on it.
The MediPen, a legal way to consume CBD, which, unlike tetrahydrocannabinol (THC), is non-psychoactive, has been on sale for a year now and drew very positive reviews, relieving the pain of people with everything from depression and anxiety to arthritis and fibromyalgia.
It has been consulting with a group of production and regulatory support pharmacists from the NHS for the past few months, who have been testing their proprietary cannabis oil formulation.
A detailed public report outlining the testing process and extraction methodology will follow, and though it is only about confirming purity and cannabinoid profile at this stage, this is a big first step for the medical cannabis industry in the UK.